Jiangsu Hengrui Pharmaceuticals (HKG:1276) received Chinese regulatory approval to begin clinical trials of two experimental medicines, according to Hong Kong bourse filings Wednesday.
Shares of the pharma company rose over 2% in morning trade Thursday.
The company said it secured the National Medical Products Administration's nod to study SHR-2173 as a treatment for primary membranous nephropathy, an autoimmune kidney disease.
Meanwhile, the regulator also approved Jiangsu's request to evaluate HRS-9821 in chronic obstructive pulmonary disease, a lung condition.
Clinical trials for both drugs will begin in the near future, the firm said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。